Concepedia

Joseph R. Garlich

JR

Statistics

Publications

20

Citations

1.2K

H-Index

17

Active since

1981

Affiliations

SignalRx Pharmaceuticals (United States)(Current)

University of California San Diego

Rady Children's Hospital-San Diego

University of Arizona

Emory University

Joseph R. Garlich is an author at SignalRx Pharmaceuticals (United States) specializing in medicine, pharmacology, and oncology.

Top concepts

Publications per year

1981–2020

20

Publications

20

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

Joseph R. Garlich, Pradip De, Nandini Dey et al. · Cancer Research · 2008 · 276 citations

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Daruka Mahadevan, E. Gabriela Chiorean, Wayne B. Harris et al. · European Journal of Cancer · 2012 · 131 citations

, , +8

Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis

Forest H. Andrews, Alok R. Singh, Shweta Joshi et al. · Proceedings of the National Academy of Sciences · 2017 · 119 citations · Full text

Recent advances in the chemistry of spinosyns

Gary D. Crouse, Thomas C. Sparks, Joseph R. Schoonover et al. · Pest Management Science · 2001 · 97 citations

Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.

John E. Bayouth, Daniel J. Macey, Leela P. Kasi et al. · PubMed · 1995 · 73 citations

1–5 of 20